Ceritinib

Chemical formula: C₂₈H₃₆ClN₅O₃S  Molecular mass: 558.135 g/mol  PubChem compound: 57379345

Therapeutic indications

Ceritinib is indicated for:

First-line treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)

Population group: only adults (18 years old or older)

Ceritinib as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

Ceritinib as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2018: ZYKADIA Hard capsule
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈